Last Friday, CNBC stock guru Jim Cramer did a segment on diabetes, highlighting Dexcom and Insulet. He mentioned the combined efforts of the two companies to develop a pod with a built-in continuous glucose monitor. Both stock were up nicely on Monday. Insulet (PODD) hit a multi-year high of nearly $19 per share.
Too bad none of the Jackwagons in the FDA own any Insulet stock… maybe things would move along a little faster:X